EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Respiratory Syncytial Virus Hospitalizations Among Adults in Thailand: A Nationwide Retrospective Observational Study (RSV‐HAT)

Kanrutai Jarottammarat iD, Kanokkarn Pinyopornpanish iD, Chadakan Yan iD, Bussakorn Mahakkanukrauh iD, Otavio Cintra iD, Adriana Guzman-Holst iD, Phichayut Phinyo iD, Wipa Reechaipichitkul iD

Influenza and Other Respiratory Viruses · 2026

DOI: 10.1111/irv.70263 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Influenza and Other Respiratory Viruses, 2026. Verfasst von Kanrutai Jarottammarat und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Hospitalization. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GlaxoSmithKline (GSK Study ID VEO-002142).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Respiratory syncytial virus (RSV) is a major cause of acute respiratory infection (ARI) in adults, especially older individuals, yet data on burden in Thailand are limited. This study aimed to describe clinical characteristics and mortality risk factors of RSV‐related hospitalizations in Thai adults.

Methods

We conducted a retrospective analysis using Thailand's national hospital database, including adults aged ≥ 18 years hospitalized with RSV‐associated ARIs between June 2016 and September 2024, identified using ICD‐10 codes J12.1, J20.5, J21.0, and B97.4. Demographics, case fatality ratio, and healthcare resource utilization were assessed. Multivariable logistic regression identified predictors of in‐hospital mortality, and Kaplan–Meier analysis estimated 60‐day overall survival by age and comorbidity status.

Results

Among 1595 RSV‐related hospitalizations, the mean age was 66.5 years; 72.0% were aged ≥60 years and 78.4% had ≥ 1 comorbidity, most commonly hypertension, diabetes, chronic respiratory disease, and chronic heart disease. The median length of stay (LOS) was 7 days, 17.3% required oxygen therapy, and 8.2% received invasive mechanical ventilation (IMV). The in‐hospital mortality was 9.53%. Mortality was independently associated with age ≥ 75 years (mOR 1.83, p = 0.019), LOS ≥ 7 days (1.95, p = 0.001), IMV (2.94, p < 0.001), pneumonia (4.10, p < 0.001), and acute myocardial infarction (3.05, p = 0.005). The 60‐day survival rate was 88.2%, declining to 84.0% in patients aged ≥ 75 years ( p < 0.001) and 87.1% in those with comorbidities versus 92.2% in those without ( p = 0.013).

Conclusions

RSV causes substantial morbidity and mortality in Thai adults, especially those aged ≥ 75 years and with chronic comorbidities, underscoring the need for strengthened RSV surveillance and prevention strategies. Trial Registration: Thai Clinical Trials Registry: TCTR20250929005

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsHospitalizationHumansThailandRetrospective StudiesFemaleAgedMiddle AgedMaleAdultAged, 80 and overHospital MortalityRisk FactorsRespiratory Syncytial Virus, HumanYoung AdultAdolescentLength of Stay

Stichwörter der Autor:innen

Thailandadulthospitalizationmortalityrespiratory syncytial virus

Autor:innen und Institutionen

  • Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
  • Allergy and Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Medical Affairs, Vaccines, GSK, Bangkok, Thailand.
  • Medical Affairs, Vaccines, International, GSK, Sao Paulo, Brazil.
  • RWE & HO Research, GSK, London, UK.
  • Center for Clinical Epidemiology and Clinical Statistics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

ORCID-Profile: Kanrutai Jarottammarat, Kanokkarn Pinyopornpanish, Chadakan Yan, Bussakorn Mahakkanukrauh, Otavio Cintra, Adriana Guzman-Holst, Phichayut Phinyo, Wipa Reechaipichitkul

Förderung

  • GlaxoSmithKline (GSK Study ID VEO-002142)

Zitieren

APA

Jarottammarat, K., Pinyopornpanish, K., Yan, C., Mahakkanukrauh, B., Cintra, O., Guzman-Holst, A., Phinyo, P., & Reechaipichitkul, W. (2026). Respiratory Syncytial Virus Hospitalizations Among Adults in Thailand: A Nationwide Retrospective Observational Study (RSV‐HAT). Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70263

Vancouver

Jarottammarat K, Pinyopornpanish K, Yan C, Mahakkanukrauh B, Cintra O, Guzman-Holst A, et al. Respiratory Syncytial Virus Hospitalizations Among Adults in Thailand: A Nationwide Retrospective Observational Study (RSV‐HAT). Influenza and Other Respiratory Viruses. 2026. doi:10.1111/irv.70263

BibTeX
@article{Jarottammarat2026,
  author = {Jarottammarat, Kanrutai and Pinyopornpanish, Kanokkarn and Yan, Chadakan and Mahakkanukrauh, Bussakorn and Cintra, Otavio and Guzman-Holst, Adriana and Phinyo, Phichayut and Reechaipichitkul, Wipa},
  title = {Respiratory Syncytial Virus Hospitalizations Among Adults in Thailand: A Nationwide Retrospective Observational Study (RSV‐HAT)},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2026},
  doi = {10.1111/irv.70263}
}
Kostenlos starten →